Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Québec, Canada; Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, Québec, Canada.
Universidade Nove de Julho (UNINOVE), São Paulo, São Paulo, Brazil.
J Affect Disord. 2021 May 15;287:19-25. doi: 10.1016/j.jad.2021.03.022. Epub 2021 Mar 11.
There is lack of recent information on the prescribing trends of antidepressants and coprescription with other psychotropic medications in the United Kingdom (UK) pediatric population.
Using the Clinical Practice Research Datalink, we estimated the annual rates of patients newly prescribed an antidepressant (selective serotonin reuptake inhibitors (SSRIs), other newer generation antidepressants, and tricyclic antidepressants (TCAs)) and the percentage of new users of antidepressants with a same-day coprescription for other psychotropic medications. We also estimated the prevalence of patients with antidepressant prescriptions and percentage of coprescription for other psychotropic medications.
After a 42% decline from 2000 to 2005, the rate of patients newly prescribed an antidepressant increased from 2006 onwards. From 2008 to 2018, the rate increased from 254.3 to 471.2 per 100,000 person-years (rate ratio 1.97, 95% confidence interval 1.96-1.99). The rate was higher in females and adolescents aged 15 to 17. SSRIs were most commonly prescribed (70% of all antidepressant prescriptions). Overall, 4.7% of patients newly prescribed an antidepressant had at least one same-day coprescription for another psychotropic medication. During the study period, coprescription rose from 2.6% to 6.4% and was more frequent in males. In 2018, most coprescriptions were anxiolytics and hypnotics (63%) and antipsychotics (26%). Trends in prevalent prescriptions corresponded to trends in new prescriptions.
By using a primary care database, we did not have information on prescriptions from specialists or during hospitalizations.
During the last decade, antidepressant prescriptions and psychotropic coprescription in primary care increased in UK children and adolescents.
目前缺乏英国（UK）儿科人群中抗抑郁药的处方趋势以及与其他精神药物同时开具处方的最新信息。
我们使用临床实践研究数据库，估算了新处方抗抑郁药（选择性 5-羟色胺再摄取抑制剂（SSRIs）、其他新型抗抑郁药和三环抗抑郁药（TCAs））的患者年度比率，以及新使用抗抑郁药的患者中与其他精神药物同日开具处方的比例。我们还估算了有抗抑郁药处方的患者的患病率和其他精神药物的处方比例。
从 2000 年到 2005 年下降了 42%之后，新处方抗抑郁药的比例从 2006 年开始上升。从 2008 年到 2018 年，该比例从 254.3/100,000人年增加到 471.2/100,000 人年（比率为 1.97，95%置信区间为 1.96-1.99）。女性和 15 至 17 岁的青少年中该比例更高。最常开具的是 SSRIs（所有抗抑郁药处方的 70%）。总体而言，有 4.7%的新处方抗抑郁药患者至少有一天同时开具了另一种精神药物。在研究期间，共开处方的比例从 2.6%上升到 6.4%，且在男性中更为常见。2018 年，最常见的共开处方是抗焦虑药和催眠药（63%）和抗精神病药（26%）。流行处方的趋势与新处方的趋势相对应。
由于使用初级保健数据库，我们没有专家处方或住院期间的信息。
在过去十年中，英国儿童和青少年的初级保健中抗抑郁药处方和精神药物共开处方的数量有所增加。
